Cargando…

Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model

PURPOSE: Ipatasertib, a potent and highly selective small-molecule inhibitor of AKT, is currently under investigation for treatment of cancer. Ipatasertib is a substrate and a time-dependent inhibitor of CYP3A4. It exhibits non-linear pharmacokinetics at subclinical doses in the clinical dose escala...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jing, Jing, Chen, Yuan, Musib, Luna, Jin, Jin Y., Cheung, Kit Wun Kathy, Yoshida, Kenta, Sane, Rucha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054915/ https://www.ncbi.nlm.nih.gov/pubmed/35428895 http://dx.doi.org/10.1007/s00280-022-04434-2

Ejemplares similares

Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function
por: Sane, Rucha, et al.
Publicado: (2021)

Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer
por: Sutaria, Dhruvitkumar S., et al.
Publicado: (2022)

Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics
por: Cheeti, Sravanthi, et al.
Publicado: (2020)

Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications
por: Sutaria, Dhruvitkumar S., et al.
Publicado: (2022)

Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study
por: Kotani, Naoki, et al.
Publicado: (2022)

Exposure–Response‐Based Product Profile–Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer
por: Zhu, Rui, et al.
Publicado: (2019)

Quantitative Prediction of OATP‐Mediated Drug‐Drug Interactions With Model‐Based Analysis of Endogenous Biomarker Kinetics
por: Yoshida, Kenta, et al.
Publicado: (2018)

Role of cytochrome P450 in drug interactions
por: Bibi, Zakia
Publicado: (2008)

Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities
por: Schink, Michael, et al.
Publicado: (2017)

Effects of Tenapanor on Cytochrome P450‐Mediated Drug‐Drug Interactions
por: Johansson, Susanne, et al.
Publicado: (2017)

Retraction: Role of cytochrome P450 in drug interactions
por: Bibi, Zakia
Publicado: (2014)

Cytochrome P450 Enzymes and Drug Metabolism in Humans
por: Zhao, Mingzhe, et al.
Publicado: (2021)

Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo
por: Wang, Yiran, et al.
Publicado: (2020)

In Silico Prediction of Drug–Drug Interactions Mediated by Cytochrome P450 Isoforms
por: Dmitriev, Alexander V., et al.
Publicado: (2021)

Deuterium isotope effects in drug pharmacokinetics II: Substrate-dependence of the reaction mechanism influences outcome for cytochrome P450 cleared drugs
por: Sun, Hao, et al.
Publicado: (2018)

The Development and Validation of a Novel “Dual Cocktail” Probe for Cytochrome P450s and Transporter Functions to Evaluate Pharmacokinetic Drug-Drug and Herb-Drug Interactions
por: Kwon, Mihwa, et al.
Publicado: (2020)

Use of Drugs that Act on the Cytochrome P450 System in the Elderly
por: Cabrera, Marcos A S, et al.
Publicado: (2009)

Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children
por: Aka, Ida, et al.
Publicado: (2017)

Pharmacokinetic Interactions of Herbs with Cytochrome P450 and P-Glycoprotein
por: Cho, Hyun-Jong, et al.
Publicado: (2015)

Pharmacokinetics, toxicity, and cytochrome P450 modulatory activity of plumbagin
por: Sumsakul, Wiriyaporn, et al.
Publicado: (2016)

Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults
por: Armani, Sara, et al.
Publicado: (2017)

Physiologically‐Based Pharmacokinetic Modeling for the Prediction of a Drug–Drug Interaction of Combined Effects on P‐glycoprotein and Cytochrome P450 3A
por: Otsuka, Yukio, et al.
Publicado: (2020)

Drug-drug interaction of acetaminophen and roxithromycin with the cocktail of cytochrome P450 and hepatotoxicity in rats
por: Liu, Xiang, et al.
Publicado: (2020)

Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants
por: Hoch, Matthias, et al.
Publicado: (2022)

Comparative Cytochrome P450 In Vitro Inhibition by Atypical Antipsychotic Drugs
por: Gervasini, Guillermo, et al.
Publicado: (2013)

An update on the role of intestinal cytochrome P450 enzymes in drug disposition
por: Xie, Fang, et al.
Publicado: (2016)

Effect of health foods on cytochrome P450-mediated drug metabolism
por: Sasaki, Takamitsu, et al.
Publicado: (2017)

A history of the roles of cytochrome P450 enzymes in the toxicity of drugs
por: Guengerich, F. Peter
Publicado: (2020)

Inflammatory signaling on cytochrome P450-mediated drug metabolism in hepatocytes
por: Wang, Xiaokang, et al.
Publicado: (2022)

Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?
por: Lammers, Laureen A., et al.
Publicado: (2017)

Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam
por: Perkins, Everett J., et al.
Publicado: (2017)

CRISPR knockout rat cytochrome P450 3A1/2 model for advancing drug metabolism and pharmacokinetics research
por: Lu, Jian, et al.
Publicado: (2017)

Highly Cytotoxic Copper(II) Mixed-Ligand Quinolinonato Complexes: Pharmacokinetic Properties and Interactions with Drug Metabolizing Cytochromes P450
por: Medvedíková, Martina, et al.
Publicado: (2023)

African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development
por: Rajman, Iris, et al.
Publicado: (2017)

A comprehensive evaluation in clinic and physiologically‐based pharmacokinetic modeling and simulation to confirm lack of cytochrome P450–mediated drug–drug interaction potential for pomotrelvir
por: Yang, Ziping, et al.
Publicado: (2023)

Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.
por: Meyer, U. A.
Publicado: (1996)

Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule
por: Mishra, Nitish K, et al.
Publicado: (2010)

Role of cytochrome P450 genotype in the steps toward personalized drug therapy
por: Cavallari, Larisa H, et al.
Publicado: (2011)

Cytochrome P450 enzyme mediated herbal drug interactions (Part 1)
por: Wanwimolruk, Sompon, et al.
Publicado: (2014)

Cytochrome P450 enzyme mediated herbal drug interactions (Part 2)
por: Wanwimolruk, Sompon, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_du7c11hf79kgem2qtvjgn80qd5